Overview

Trial of Cell Based Therapy for DMD

Status:
RECRUITING

Trial end date:
2027-03-03

Target enrollment:

Participant gender:

Summary

This is a single-center, single-arm, interventional phase 1 trial to evaluate the safety and tolerability of local injection of induced pluripotent stem cell (iPSC)- derived CD54+ allogeneic muscle progenitor cells in individuals with Duchenne muscular dystrophy (DMD)

Phase:

PHASE1

Details

Lead Sponsor:

Masonic Cancer Center, University of Minnesota

Collaborators:

Duchenne UK
Parent Project Muscular Dystrophy

Treatments:

Tacrolimus